Madras HC: Police Superintendent not Liable For IO’s Delay In Filing Chargesheet or Closure Report || Supreme Court: Provident Fund Dues Have Priority over a Bank’s Claim under the SARFAESI Act || SC Holds Landowners Who Accept Compensation Settlements Cannot Later Seek Statutory Benefits || Supreme Court: Endless Investigations and Long Delays in Chargesheets Can Justify Quashing || Delhi HC: Arbitrator Controls Evidence and Appellate Courts Cannot Reassess Facts || Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint || Delhi HC: ED Can Search Anyone Holding Crime Proceeds, not Just Those Named in Complaint || Delhi HC: Economic Offender Cannot Seek Travel Abroad For Medical Treatment When Available In India || SC: Governors and President Have No Fixed Timeline To Assent To Bills; “Deemed Assent” is Invalid || SC: Assigning a Decree For Specific Performance of a Sale Agreement Does Not Require Registration

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :